Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, reposted from Syed Saad Mahmood on LinkedIn:
”Thank you very much for the opportunity to discuss the results of the API-CAT Study adressing the extended anticoagulant treatment in patients with cancer associated thrombosis!”
Syed Saad Mahmood, System Director, Cardio-Oncology at Catholic Health, shared on LinkedIn:
”*St Francis Heart Center, NY CardioOncology Journal Club*
Dr. Isabelle Mahe (Université Paris Cité, France) joined us to discuss *API-CAT trial* evaluating whether among active cancer patients with venous thromboembolism, tx with a reduced dose oral anticoagulant is effective in preventing recurrent thromboembolic events and reduced bleeding”
Find more from Cardio-Oncology Journal Club.
Watch the full episode here.
Stay updated on the latest advancements in hemostasis research with Hemostasis Today.
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care
-
Jun 24, 2026, 07:46Wolfgang Miesbach: WFH’s First AAV Gene Therapy Chapter Marks a New Era in Hemophilia Care
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting